Immune mediated therapy and MEK inhibition: preclinical assessment of immunobiology and combination activity in vitro and in vivo

Eitemau Tebyg

• The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment
  gan: Poon, Edmund, et al.
  Cyhoeddwyd: (2017)
• A mouse GITRl fusion protein drives T cell activation and antitumor activity in preclinical mouse models of cancer
  gan: Leyland, Rebecca, et al.
  Cyhoeddwyd: (2015)
• The prediction of the allergenicity food proteins by combining an in vitro and an in vivo model
  gan: Van Bilsen, Jolanda, et al.
  Cyhoeddwyd: (2015)
• Combined Treatment with MEK and mTOR Inhibitors is Effective in In Vitro and In Vivo Models of Hepatocellular Carcinoma
  gan: Liu, Xianqiong, et al.
  Cyhoeddwyd: (2019)
• Combined MEK and Pi3′-kinase inhibition reveals synergy in targeting thyroid cancer in vitro and in vivo
  gan: ElMokh, Oussama, et al.
  Cyhoeddwyd: (2017)